Research article · 2013
Conference abstractPublished 25 Aug 2015
Involvement of genetics in poor outcomes in anticoagulation therapy
Newcastle University, UK
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Warfarin is commonly prescribed for the treatment and prevention of thromboembolic disorders. Anticoagulation response to warfarin during the initiation of therapy is variable. This is mainly due to the drug’s narrow therapeutic window and the wide inter-individual variability in warfarin dose requirement which makes the prediction of an accurate dose for individual patients difficult despite the use of standard induction regimens and frequent INR monitoring. As a result, some patients who are sensitive to warfarin are at increased risk of bleeding due to over-dosing whereas some are at increased risk of thrombosis due to under-dosing. Approximately half of the variability in warfarin dose requirement is explained by patient age, body size and CYP2C9 and VKORC1 genes. A personalised approach to warfarin dosing using genetic information has the potential to improve the safety and efficacy of anticoagulation therapy. The author will be presenting the results of prospective trials exploring the potential benefits of pharmacogenetics-based therapy and the potential for future implementation of pharmacogenetics-guided therapy in the clinic setting.
Subjects
Genetics & Molecular BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · 26 May 2016
Genetic variability of ERCC1 and ERCC2 genes involved in the nucleotide excision repair pathway influences the treatment outcome of gastric cancer
Research article · 28 Sep 2015
Genetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma
Review article · 2013
Genetic Syndromes and Genes Involved in the Development of the Female Reproductive Tract: A Possible Role for Gene Therapy
Conference abstract · 26 Oct 2016
COST action BM1207: Involving all stakeholders to overcome challenges of genetic therapy development for Duchenne muscular dystrophy
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectGenetics & Molecular Biology
- BylineArticles whose byline prints “Farhad Kamali”
